Dr Reddy's inks licensing pact with Takeda to sell gastrointestinal drug

New Delhi: Dr Reddy's Laboratories, a Hyderabad-based firm, and Takeda Pharmaceutical entered a non-exclusive licensing pact to market 10mg and 20mg Vonoprazan tablets, a PCAB for reflux esophagitis and acid peptic disorders, in India. CEO MV Ramana highlighted the strategic collaboration. Shares rose 0.33% to Rs 6,665.10 on BSE.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/wtplLcq
via IFTTT